A 74-year-old male presented with refractory cough despite inhaled corticosteroids and bronchodilators. Clinical assessment was non-contributory. Lung function tests showed reduced small airway function (50% predicted), a positive mannitol challenge test and an elevated fractional exhaled nitric oxide (FeNO) of 120 parts per billion (ppb) (normal range < 25 ppb in adults). A bronchoscopy showed mild lymphocytic inflammation on endobronchial biopsy with a neutrophilic lavage but no eosinophilia. Nebulised corticosteroids were trialled with mild clinical improvement but FeNO remained elevated (270 ppb).
The patient had reported improvement in cough with oral prednisolone, with worsening on dose reduction. A trial of azathioprine had no effect. Positron emission tomography (PET) showed fludeoxyglucose avidity consistent with thoracic aortitis and major branches of aorta upper arms. Anti-nuclear, anti-cyclic citrullinated peptide and antineutrophil cytoplasmic antibodies were negative. Despite a normal total immunoglobulin G (IgG), immunoglobulin G4 (IgG4) subclass was elevated at 3.08 g/L (<1.32) (peaking at 4.30 g/L). There was a slight eosinophilia (0.5-1.0) (normal <0.41 10 9 /L). CT thorax showed mild bronchial wall thickening but no pulmonary infi ltrates. Because of urological symptoms, magnetic resonance imaging was undertaken; this demonstrated prostatic infl ammation. A clinical diagnosis of IgG4-related systemic disease (IgG4-RD) was made, based on respiratory manifestations, aortic and prostatic infl ammation. Tissue diagnosis was not possible. Pulsed methylprednisolone was initiated followed by oral steroids and methotrexate. There was initial symptomatic improvement in respiratory symptoms and follow-up PET showed resolution of fl udeoxyglucose avidity. Symptoms increased on steroid reduction with complications on higher doses. Higher dose methotrexate was not tolerated and interval PET-CT showed recurrence with thoracic aorta uptake. Rituximab was initiated with PET-CT scan 8 months later demonstrating response. FeNO has acted as a biomarker of disease activity with the most recent measurement 70 ppb.
Case 2 -Weight loss with narrowed bronchus
An 80-year-old male presented with unexplained 13 kg weight loss over 6 months on a background of autoimmune pancreatitis. Serum electrophoresis showed a raised total IgG with elevated IgG subclasses; notably IgG4 was 16 g/L (< 1.32). CT thorax, abdomen and pelvis revealed narrowing of the right upper lobe bronchus. Bronchoscopy revealed no obstruction but endobronchial biopsy showed eosinophilia and a plasmacytic infi ltrate negative for IgG4 staining ( Figure  1 ). The patient declined to attend the Autoimmune Connective Tissue Disease Clinic to consider IgG4-RD systemic treatment options (for both his autoimmune pancreatitis and endobronchial disease).
Case 3 -Incidental pulmonary nodules
A 62-year-old female presented with palpitations. CT coronary angiogram revealed cavitating lung nodules ( Figure  2 ). She had no respiratory or constitutional symptoms. CT pulmonary angiography and abdominopelvic CT revealed no pulmonary emboli or malignancy. Both vasculitic screen and broncho-alveolar lavage were unremarkable. She was treated empirically for atypical infection. The nodules persisted on interval CT, leading to a video-assisted surgical lung biopsy, which showed peribronchial interstitial chronic infl ammation with nodular lymphoid hyperplasia ( Figure 3) . Immunohistochemistry demonstrated over 50% IgG-positive cells which were positive for IgG4. IgG subclasses were measured in peripheral blood with a raised IgG4 of 2.77 g/L. A diagnosis of asymptomatic IgG4 pulmonary disease was made. PET did not show increased avidity in the pulmonary nodules or elsewhere. Management was expectant as she was asymptomatic and concerned about corticosteroid use.
Discussion
IgG is the most abundant immunoglobulin in the human immune system, with 4 subtypes. IgG4 is the least prevalent subtype (1-4%) and least understood. 1 Theories about the role of IgG4 include:
• Anti-inflammatory activity due to poor complement activation via C1q and Fc receptors 2 • 'Blocking antibody' function by competing with IgE for allergens 1 IgG4-RD is increasingly recognised, with autoimmune pancreatitis one of the first entities described. 3 Pathophysiological mechanisms are still incompletely understood. The main process seems to be fi bro-infl ammatory characterised by tumour-like lesions, lymphoplasmacytic infi ltrate, storiform fi brosis, and elevated serum IgG4. 4 Almost any organ can be involved but common manifestations are pancreatitis, sclerosing cholecystitis, sclerosing sialadenitis, dacryoadenitis, lymphadenopathy and retroperitoneal fi brosis. 4 Intrathoracic manifestations vary from 14-54% in prevalence. 5 
Diagnosis
Several diagnostic criteria exist with biopsy confi rmation strongly recommended to also exclude malignancy and vasculitis 6, 7 The major histopathological features are outlined in Table 1 . These features may be absent or less prominent in certain organs such as the lung. 8 Other histopathological features are the number of IgG4-positive (IgG4+) plasma cells per high power fi eld (range of 10-200 per hpf) and the ratio of IgG4+/IgG+ plasma cells. The cut-offs depend on the type and site of biopsy, for example in the lung, > 50 IgG4+ per hpf are needed for a surgical specimen vs. > 20 in a needle biopsy. 9, 10 Elevated serum levels of IgG4 (> 1.36 g/l) can be a feature in IgG4-RD; 11 however, 3-30% of patients with IgG4-RD can have normal concentrations. [12] [13] [14] [15] [16] Serum IgG4 can be a useful biomarker to monitor disease and response to glucocorticoids if elevated at presentation. 17 More elevated levels can occur in more extensive disease. [18] [19] [20] [21] However, raised serum IgG4 levels can be seen in other conditions, e.g. rheumatoid arthritis, limiting its value alone without biopsy. 22, 23 Plasmablasts are found in high concentrations in IgG4-RD, regardless of serum IgG4, and may correlate more strongly with disease activity. 18 Peripheral eosinophilia is present in around 30% 24 with tissue eosinophilia being notable in some cases. 10 Theories of the role of the eosinophil in IgG4-RD include antigen presentation, release of profi brotic factors, and promotion of plasma cell survival for IgG4 production. 
IgG4-RD pulmonary and pleural manifestations
IgG4-RD in the lung and pleural cavity 26 can present insidiously and symptoms generally refl ect disease location, e.g. dyspnoea, cough, haemoptysis and chest pain. It usually presents in middle to late age with a male preponderance. 4 Individuals may have been treated for asthma with poor treatment response. Patients can present incidentally or diagnosis may be made due to detection of IgG4+ plasma cell infi ltration in multiple organs (multi-organ lymphoproliferative syndrome or MOLPS). 27, 28 Up to 40% can present with concomitant allergy. 29 Radiological appearances vary but bronchovascular thickening is characteristic. Other features include pulmonary nodules, ground-glass opacities, pleural thickening, interstitial fi brosis and lymphadenopathy. 30 PET can be helpful in identifying extra-thoracic disease sites such as aortitis, as well as monitoring disease activity. 31 
Management
First-line therapy is usually with systemic glucocorticoids. 17 For remission-induction, prednisolone at a dose of 30-40 mg is commonly started. Pulsed intravenous methylprednisolone (1-3 doses) is an option for induction of multisystem disease. Clinical response is assessed using serial serum IgG4, if elevated at diagnosis, and radiological response. A quick and favourable response to glucocorticoids is usual in most cases, but in some this is not sustained on dose reduction.
A case of bronchial disease has been treated successfully with inhaled steroids. 32 Relapse often occurs following glucocorticoid discontinuation. 33 Immunomodulation with azathioprine, methotrexate and mycophenolate mofetil is recommended based on best clinical practice, case series and NHS England guidance, but no prospective controlled data currently exist. 17, 26, 34 Anti-CD20 monoclonal therapy (rituximab) has also been used with success in refractory cases, with patients demonstrating prompt clinical, radiological and serological responses. [35] [36] [37] Rituximab is now approved by NHS England as a third-line agent for highly selected resistant cases. 34 
Conclusion
IgG4-RD is rare but important due to its potential for morbidity if not recognised and treated early. It can mimic more common respiratory conditions such as asthma but go undiagnosed. It should be considered in cases with unexplained chronic infl ammatory endobronchial biopsies, refractory asthma or multi-organ infl ammation. This paper illustrates three varied respiratory presentations and different diagnostic pathways. Biopsy confi rmation and early inter-specialty involvement may be required for optimal management. 
